scholarly journals Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus

2015 ◽  
Vol 196 (1) ◽  
pp. 80-90 ◽  
Author(s):  
Yiming Yin ◽  
Seung-Chul Choi ◽  
Zhiwei Xu ◽  
Leilani Zeumer ◽  
Nathalie Kanda ◽  
...  
2016 ◽  
Vol 311 (1) ◽  
pp. F217-F226 ◽  
Author(s):  
Wei Li ◽  
Hu Li ◽  
Mu Zhang ◽  
Mengqi Wang ◽  
Youxiu Zhong ◽  
...  

Systemic lupus erythematosus (SLE) is a serious disorder of immune regulation characterized by overproduction of autoantibodies, lupus nephritis, CD4+ T cell aberrant activation, and immune complex-mediated inflammation. The chronic graft vs. host disease (cGVHD) mouse model is a well-established model of SLE. Quercitrin is a natural compound found in Tartary buckwheat with a potential anti-inflammatory effect that is used to treat heart and vascular conditions. In our previous study, we determined that quercitrin is an immunosuppressant with beneficial effects in mouse models of immune diseases. We hypothesized that quercitrin could prevent lupus nephritis in the cGVHD mouse model by decreasing the production of autoantibodies and inflammatory cytokines, and reducing immune cell activation. cGVHD was induced by injecting DBA/2 spleen cells into the tail vein of BDF1 mice. The cGVHD mice exhibited significant proteinuria, which is a marker of nephritis. Quercitrin decreased the number of serum antibodies, CD4+ T cell activation, as well as the expression levels of T-bet, GATA-3, and selected cytokines. Moreover, quercitrin treatment decreased the expression of inflammatory genes and cytokines in the kidney, as well as in peritoneal macrophages. In addition, quercitrin inhibited LPS-induced cytokines as well as the phosphorylation of ERK, p38 MAPK, and JNK in Raw264.7 cells. Overall, quercitrin ameliorated the symptoms of lupus nephritis in the cGVHD mouse model, which may be due to the inhibition of CD4 T cell activation and anti-inflammatory effects on macrophages.


2012 ◽  
Vol 64 (9) ◽  
pp. 2953-2963 ◽  
Author(s):  
Shu Ding ◽  
Yunsheng Liang ◽  
Ming Zhao ◽  
Gongping Liang ◽  
Hai Long ◽  
...  

2015 ◽  
Vol 182 (1) ◽  
pp. 1-13 ◽  
Author(s):  
J. P. Mackern-Oberti ◽  
J. Obreque ◽  
G. P. Méndez ◽  
C. Llanos ◽  
A. M. Kalergis

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1433 ◽  
Author(s):  
Chuang ◽  
Tan

T cells play a critical role in the pathogenesis of systemic lupus erythematosus (SLE), which is a severe autoimmune disease. In the past 60 years, only one new therapeutic agent with limited efficacy has been approved for SLE treatment; therefore, the development of early diagnostic biomarkers and therapeutic targets for SLE is desirable. Mitogen-activated protein kinase kinase kinase kinases (MAP4Ks) and dual-specificity phosphatases (DUSPs) are regulators of MAP kinases. Several MAP4Ks and DUSPs are involved in T-cell signaling and autoimmune responses. HPK1 (MAP4K1), DUSP22 (JKAP), and DUSP14 are negative regulators of T-cell activation. Consistently, HPK1 and DUSP22 are downregulated in the T cells of human SLE patients. In contrast, MAP4K3 (GLK) is a positive regulator of T-cell signaling and T-cell-mediated immune responses. MAP4K3 overexpression-induced RORγt–AhR complex specifically controls interleukin 17A (IL-17A) production in T cells, leading to autoimmune responses. Consistently, MAP4K3 and the RORγt–AhR complex are overexpressed in the T cells of human SLE patients, as are DUSP4 and DUSP23. In addition, DUSPs are also involved in either human autoimmune diseases (DUSP2, DUSP7, DUSP10, and DUSP12) or T-cell activation (DUSP1, DUSP5, and DUSP14). In this review, we summarize the MAP4Ks and DUSPs that are potential biomarkers and/or therapeutic targets for SLE.


1989 ◽  
Vol 9 (6) ◽  
pp. 469-476 ◽  
Author(s):  
Stanislaw Sierakowski ◽  
Eugene J. Kucharz ◽  
Robert W. Lightfoot ◽  
James S. Goodwin

1991 ◽  
Vol 34 (5) ◽  
pp. 561-571 ◽  
Author(s):  
David A. Fox ◽  
Jo Ann Millard ◽  
Jonathan Treisman ◽  
Wendy Zeldes ◽  
Alice Bergman ◽  
...  

2018 ◽  
Vol 25 (1) ◽  
pp. 38-54
Author(s):  
C. Nicolás Téllez ◽  
José J. Siachoque ◽  
S. Juan Siachoque ◽  
J. María Alejandra Siachoque ◽  
M. Heber Siachoque

Sign in / Sign up

Export Citation Format

Share Document